{"id":"atgc-110","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Pneumonitis"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, ATGC-110 blocks the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.","oneSentence":"ATGC-110 is a small molecule that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:56.061Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT05623410","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines","status":"UNKNOWN","sponsor":"ATGC Co., Ltd.","startDate":"2022-10-11","conditions":"Glabellar Frown Lines","enrollment":300},{"nctId":"NCT04281095","phase":"PHASE1, PHASE2","title":"A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines","status":"COMPLETED","sponsor":"ATGC Co., Ltd.","startDate":"2019-11-01","conditions":"Glabellar Frown Lines","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Clostridium Botulinum Type A"],"phase":"phase_3","status":"active","brandName":"ATGC-110","genericName":"ATGC-110","companyName":"ATGC Co., Ltd.","companyId":"atgc-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"ATGC-110 is a small molecule that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}